Zhejiang East-Asia Pharmaceutical (605177.SH): The raw material drug Lu Likang received the South Korean raw material drug registration certificate.
East Asia Pharmaceutical (605177.SH) issued an announcement that they recently received approval from the South Korean Food and Drug Administration (Korea...
Zhejiang East-Asia Pharmaceutical (605177.SH) announced that recently, the company has received the raw material drug registration certificate from the South Korean Ministry of Food and Drug Safety (Korean MFDS) for the product named Voriconazole. Voriconazole is used to treat skin superficial fungal infections caused by sensitive fungi, such as athlete's foot, body ringworm, jock itch, and can also be used for cutaneous candidiasis and tinea versicolor.
The receipt of the Voriconazole raw material drug registration certificate in South Korea marks the company's eligibility for market access in South Korea. This will have a positive impact on expanding the company's presence in the South Korean pharmaceutical market, thus promoting the sales of Voriconazole raw material drugs in other overseas markets.
Related Articles

VIVA BIOTECH (01873) spent HKD 428,000 to repurchase 301,000 shares on May 9th.

CHINAHONGQIAO (01378) spent HK$273 million to repurchase 19.667 million shares on May 9th.

STANCHART (02888) spent 13.642 million pounds on May 8th to repurchase 1.287 million shares.
VIVA BIOTECH (01873) spent HKD 428,000 to repurchase 301,000 shares on May 9th.

CHINAHONGQIAO (01378) spent HK$273 million to repurchase 19.667 million shares on May 9th.

STANCHART (02888) spent 13.642 million pounds on May 8th to repurchase 1.287 million shares.

RECOMMEND

General Administration of Customs: China's goods trade imports and exports increased by 2.4% year-on-year in the first 4 months.
09/05/2025

Key details are yet to be finalized. The market's response to the US-UK trade agreement has been lukewarm.
09/05/2025

Risk assets rebounded to boost the market, Bitcoin surged back above $100,000.
09/05/2025